Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206754 | 0.81 | NFKB1 (0.50) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL21450366 | 0.80 | CA1 (0.42) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL26991593 | 0.80 | LCK (0.42) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL28834445 | 0.80 | LCK (0.41) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL25003324 | 0.79 | MALT1 (0.47) | GAACA1CA2 | |
| SCHEMBL380080 | 0.79 | DAO (0.42) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL13983816 | 0.79 | LMNA (0.46) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL7812853 | 0.78 | LCK (0.43) | ATRLCKGAACA1CA2 | |
| SCHEMBL15674780 | 0.78 | LMNA (0.42) | ATRLCKGAAPKMALOX15 | |
| SCHEMBL380561 | 0.78 | L3MBTL1 (0.49) | ATRLCKGAAPKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853746-A | Formamide compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-105658653-A | Furo- and thieno-pyridine carboxamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-2660243-A2 | SUBSTITUTED HYDROGENATED THIENO-PYRROLO[3,2-C]PYRIDINE, LIGANDS, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR USING THE ABOVE | Ivachtchenko, Alexandre Vasilievich (RU) | 2013-11-06 | — | — | EP | disclosed |
| US-20130267551-A1 | SUBSTITUTED HYDROGENATED THIENO-PYRROLO[3,2-C]PYRIDINE, LIGANDS, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR USING THE ABOVE | ALLA CHEM, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267551-A1 | SUBSTITUTED HYDROGENATED THIENO-PYRROLO[3,2-C]PYRIDINE, LIGANDS, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR USING THE ABOVE | ALLA CHEM, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-1826333-B | Diamine derivatives | DAIICHI SANKYO CO LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| CN-1688587-A | Process and intermediates for preparing thienopyrrole derivatives | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| CN-1322195-A | Substituted pyrroldinone, thizolidinone or oxazolidinone as herbicides | ZENECA LTD (GB) | 2001-11-14 | — | — | CN | disclosed |
| EP-1119547-A1 | SUBSTITUTED PYRROLIDINONE, THIAZOLIDINONE OR OXAZOLIDINONE AS HERBICIDES | Syngenta Limited (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021928-A1 | SUBSTITUTED PYRROLIDINONE, THIAZOLIDINONE OR OXAZOLIDINONE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | ATR 3360/4885LCK 3678/4885GAA 4788/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | ATR 3360/4885LCK 3678/4885GAA 4788/4885 |
| US-20130267551-A1 | SUBSTITUTED HYDROGENATED THIENO-PYRROLO[3,2-C]PYRIDINE, LIGANDS, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR USING THE ABOVE | HRH4, HRH3, HRH1 | ATR 2552/4885LCK 2880/4885GAA 4677/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | ATR 3645/4885LCK 3505/4885GAA 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.